These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25015676)

  • 21. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
    Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Zeitz J; Pantel K; Fehm T;
    Breast Cancer Res; 2011 Jul; 13(4):R71. PubMed ID: 21745383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
    BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer.
    Martín M; Custodio S; de Las Casas ML; García-Sáenz JÁ; de la Torre JC; Bellón-Cano JM; López-Tarruella S; Vidaurreta-Lazaro M; de la Orden V; Jerez Y; Márquez-Rodas I; Casado A; Sastre J; Díaz-Rubio E
    Oncologist; 2013; 18(8):917-23. PubMed ID: 23873719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial.
    Jiang ZF; Cristofanilli M; Shao ZM; Tong ZS; Song EW; Wang XJ; Liao N; Hu XC; Liu Y; Wang Y; Zeng L; Zhang M
    Ann Oncol; 2013 Nov; 24(11):2766-72. PubMed ID: 23857960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer.
    De Giorgi U; Mego M; Scarpi E; Giuliano M; Giordano A; Reuben JM; Valero V; Ueno NT; Hortobagyi GN; Cristofanilli M
    Clin Breast Cancer; 2012 Aug; 12(4):264-9. PubMed ID: 22591634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.
    Liu MC; Shields PG; Warren RD; Cohen P; Wilkinson M; Ottaviano YL; Rao SB; Eng-Wong J; Seillier-Moiseiwitsch F; Noone AM; Isaacs C
    J Clin Oncol; 2009 Nov; 27(31):5153-9. PubMed ID: 19752342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.
    Magbanua MJM; Hendrix LH; Hyslop T; Barry WT; Winer EP; Hudis C; Toppmeyer D; Carey LA; Partridge AH; Pierga JY; Fehm T; Vidal-Martínez J; Mavroudis D; Garcia-Saenz JA; Stebbing J; Gazzaniga P; Manso L; Zamarchi R; Antelo ML; Mattos-Arruda L; Generali D; Caldas C; Munzone E; Dirix L; Delson AL; Burstein HJ; Qadir M; Ma C; Scott JH; Bidard FC; Park JW; Rugo HS
    J Natl Cancer Inst; 2021 Apr; 113(4):443-452. PubMed ID: 32770247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients.
    Liu XR; Shao B; Peng JX; Li HP; Yang YL; Kong WY; Song GH; Jiang HF; Liang X; Yan Y
    Breast; 2017 Apr; 32():119-125. PubMed ID: 28157583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer.
    Stefanovic S; Deutsch TM; Riethdorf S; Fischer C; Hartkopf A; Sinn P; Feisst M; Pantel K; Golatta M; Brucker SY; Sütterlin M; Schneeweiss A; Wallwiener M
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.
    Bulfoni M; Gerratana L; Del Ben F; Marzinotto S; Sorrentino M; Turetta M; Scoles G; Toffoletto B; Isola M; Beltrami CA; Di Loreto C; Beltrami AP; Puglisi F; Cesselli D
    Breast Cancer Res; 2016 Mar; 18(1):30. PubMed ID: 26961140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic significance of circulating tumor cell enumeration and HER2 expression by a novel automated microfluidic system in metastatic breast cancer.
    Wang L; Hong R; Shi S; Wang S; Chen Y; Han C; Li M; Ye F
    BMC Cancer; 2024 Aug; 24(1):1067. PubMed ID: 39210288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer.
    Kirwan CC; Descamps T; Castle J
    Clin Transl Oncol; 2020 Jun; 22(6):870-877. PubMed ID: 31473984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
    Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
    BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.
    Bidard FC; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Cottu P; Beuzeboc P; Rolland E; Mathiot C; Pierga JY
    Breast Cancer Res; 2012 Feb; 14(1):R29. PubMed ID: 22330883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Papadaki MA; Messaritakis I; Fiste O; Souglakos J; Politaki E; Kotsakis A; Georgoulias V; Mavroudis D; Agelaki S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
    Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.
    de Kruijff IE; Sieuwerts AM; Onstenk W; Jager A; Hamberg P; de Jongh FE; Smid M; Kraan J; Timmermans MA; Martens JWM; Sleijfer S
    Int J Cancer; 2019 Aug; 145(4):1083-1089. PubMed ID: 30761532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.